Teruo Jojima

1.8k total citations · 1 hit paper
47 papers, 1.3k citations indexed

About

Teruo Jojima is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Molecular Biology. According to data from OpenAlex, Teruo Jojima has authored 47 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Endocrinology, Diabetes and Metabolism, 16 papers in Surgery and 12 papers in Molecular Biology. Recurrent topics in Teruo Jojima's work include Diabetes Treatment and Management (12 papers), Liver Disease Diagnosis and Treatment (10 papers) and Pancreatitis Pathology and Treatment (5 papers). Teruo Jojima is often cited by papers focused on Diabetes Treatment and Management (12 papers), Liver Disease Diagnosis and Treatment (10 papers) and Pancreatitis Pathology and Treatment (5 papers). Teruo Jojima collaborates with scholars based in Japan and United States. Teruo Jojima's co-authors include Yoshimasa Aso, Toshie Iijima, Kunihiro Suzuki, Isao Usui, Kikuo Kasai, Kanako Kato, Kazumi Akimoto, Yoshiyuki Hattori, Masanori Shimizu and Kohsuke Uchida and has published in prestigious journals such as SHILAP Revista de lepidopterología, Diabetes and Scientific Reports.

In The Last Decade

Teruo Jojima

44 papers receiving 1.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Evaluation of the effects of dapagliflozin, a sodium‐glucose co‐transporter‐2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non‐alcoholic fatty liver disease

2018 286 citations Kunihiro Suzuki, Kanako Kato et al. profile →

Peers

Countries citing papers authored by Teruo Jojima

Since Specialization

Citations

This map shows the geographic impact of Teruo Jojima's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Teruo Jojima with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Teruo Jojima more than expected).

Fields of papers citing papers by Teruo Jojima

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Teruo Jojima. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Teruo Jojima. The network helps show where Teruo Jojima may publish in the future.

Co-authorship network of co-authors of Teruo Jojima

This figure shows the co-authorship network connecting the top 25 collaborators of Teruo Jojima. A scholar is included among the top collaborators of Teruo Jojima based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Teruo Jojima. Teruo Jojima is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	High serum levels of CCL11/Eotaxin-1 are associated with diabetic sensorimotor polyneuropathy and peripheral nerve function but not with cardiac autonomic neuropathy in people with type 2 diabetes 2024 ·Postgraduate Medicine ·Yoshimasa Aso, Toshie Iijima, Teruo Jojima, Masahiro Saito, (unknown), (unknown), Shintaro Sakurai, Takuya Tomaru, Isao Usui	3
2	Patients with diabetes and obesity exhibit characteristics in eating and coping behaviors and personality traits 2024 ·Diabetology International ·Masahiro Saito, Isao Usui, Norio Sugawara, Teruo Jojima, Shintaro Sakurai, (unknown), Masaaki Sagara, Takuya Tomaru, Toshie Iijima, Kazutaka Shimoda, Norio Yasui‐Furukori, Yoshimasa Aso	1
3	Inhibition of IL-33 signaling ameliorate hepatic fibrosis with decreasing MCP-1 in a mouse model of diabetes and non-alcoholic steatohepatitis; comparison for luseogliflozin, an SGLT2 inhibitor 2023 ·Journal of Diabetes and its Complications ·(unknown), Teruo Jojima, Masaaki Hashiguchi, (unknown), (unknown), Shintaro Sakurai, Toshie Iijima, Takahiko Kogai, Takuya Tomaru, Isao Usui, Yoshimasa Aso	9
4	Increased Number of Mucosal-Associated Invariant T Cells Is Associated with the Inhibition of Nonalcoholic Fatty Liver Disease in High Fat Diet–Fed Mice 2022 ·International Journal of Molecular Sciences ·(unknown), Isao Usui, Teruo Jojima, Shiho Fujisaka, (unknown), (unknown), (unknown), Shintaro Sakurai, Toshie Iijima, Takuya Tomaru, Kazuyuki Tobe, Yoshimasa Aso	2
5	Acute effect of add‐on therapy with tofogliflozin, a sodium glucose co‐transporter 2 inhibitor, on 24‐hours glucose profile and glycaemic variability evaluated by continuous glucose monitoring in patients with type 2 diabetes receiving dipeptidyl peptidase‐4 inhibitors 2021 ·International Journal of Clinical Practice ·Toshie Iijima, (unknown), (unknown), (unknown), Shintaro Sakurai, Takuya Tomaru, Teruo Jojima, Isao Usui, Yoshimasa Aso	2
6	Empagliflozin increases plasma levels of campesterol, a marker of cholesterol absorption, in patients with type 2 diabetes: Association with a slight increase in high-density lipoprotein cholesterol 2021 ·International Journal of Cardiology ·Teruo Jojima, Shintaro Sakurai, (unknown), Toshie Iijima, Masahiro Saito, Takuya Tomaru, Takahiko Kogai, Isao Usui, Yoshimasa Aso	19
7	A case of hypoparathyroidism, deafness, and renal dysplasia (HDR) syndrome with a novel frameshift variant in GATA3, p.W10Cfs40, lacks kidney malformation 2020 ·SHILAP Revista de lepidopterología ·(unknown), Teruo Jojima, Takahiko Kogai, Toshie Iijima, (unknown), (unknown), (unknown), Kanako Kato, (unknown), Kazumi Akimoto, (unknown), Akira Hishinuma, Takuya Tomaru, Noriko Makita, Isao Usui, Yoshimasa Aso	3
8	Bullous pemphigoid associated with dipeptidyl peptidase‐4 inhibitor showing unfavorable outcomes despite immediate discontinuation of medication 2020 ·SHILAP Revista de lepidopterología ·(unknown), Toshie Iijima, Shintaro Sakurai, Teruo Jojima, (unknown), Shujiro Hayashi, Isao Usui, Ken Igawa, Yoshimasa Aso	3
9	Teneligliptin, a DPP-4 Inhibitor, Decreases Plasma Levels of Inflammatory Chemokines During a Standard Meal Test in Patients With Type 2 Diabetes 2020 ·The American Journal of the Medical Sciences ·Yoshimasa Aso, (unknown), Masaaki Sagara, Shintaro Sakurai, Toshie Iijima, Takuya Tomaru, Teruo Jojima, Isao Usui	7
10	Liraglutide, a GLP-1 receptor agonist, inhibits vascular smooth muscle cell proliferation by enhancing AMP-activated protein kinase and cell cycle regulation, and delays atherosclerosis in ApoE deficient mice 2017 ·Atherosclerosis ·Teruo Jojima, Kohsuke Uchida, Kazumi Akimoto, (unknown), Kazunori Yanagi, Toshie Iijima, Kunihiro Suzuki, Kikuo Kasai, Yoshimasa Aso	91
11	Circulating CD4+PD-1+ and CD8+PD-1+ T cells are profoundly decreased at the onset of fulminant type 1 diabetes and are restored by treatment, contrasting with CD4+CD25+FoxP3+ regulatory T cells 2017 ·Diabetes Research and Clinical Practice ·Toshie Iijima, Kanako Kato, Teruo Jojima, (unknown), (unknown), Kunihiro Suzuki, Yoshimasa Aso	14
12	Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes 2016 ·Diabetology & Metabolic Syndrome ·Teruo Jojima, (unknown), Toshie Iijima, Kazumi Akimoto, Kunihiro Suzuki, Yoshimasa Aso	166
13	Sitagliptin, a dipeptidyl peptidase-4 inhibitor, increases the number of circulating CD34+CXCR4+ cells in patients with type 2 diabetes 2015 ·Endocrine ·Yoshimasa Aso, Teruo Jojima, Toshie Iijima, Kunihiro Suzuki, (unknown), M. Fukushima, (unknown), Kenji Hara, Kohzo Takebayashi, Kikuo Kasai, Toshihiko Inukai	28
14	Sitagliptin, a DPP-4 inhibitor, alters the subsets of circulating CD4+ T cells in patients with type 2 diabetes 2015 ·Diabetes Research and Clinical Practice ·Yoshimasa Aso, (unknown), Masaaki Sagara, Teruo Jojima, Toshie Iijima, Kunihiro Suzuki, (unknown), Kikuo Kasai, Toshihiko Inukai	34
15	Greater Efficacy and Improved Endothelial Dysfunction in Untreated Type 2 Diabetes with Liraglutide versus Sitagliptin 2014 ·Kunihiro Suzuki, Seiichi Tanaka, Chie Aoki, Kanako Kato, Teruo Jojima, Yoshimasa Aso	8
16	The serum level of soluble CD26/dipeptidyl peptidase 4 increases in response to acute hyperglycemia after an oral glucose load in healthy subjects: association with high-molecular weight adiponectin and hepatic enzymes 2013 ·Translational research ·Yoshimasa Aso, (unknown), Kanako Kato, Teruo Jojima, Kunihiro Suzuki, Toshie Iijima, (unknown), Shigeru Mikami, Yoshiro Kubota, Toshihiko Inukai, Kikuo Kasai	21
17	Fluvastatin upregulates endothelial nitric oxide synthase activity via enhancement of its phosphorylation and expression and via an increase in tetrahydrobiopterin in vascular endothelial cells 2010 ·International Journal of Cardiology ·Chie Aoki, (unknown), Seiichi Tanaka, Kazunori Yanagi, Satoshi Ohta, Teruo Jojima, Kikuo Kasai, Hidehiro Takekawa, Koichi Hirata, Yoshiyuki Hattori	30
18	Anti-Inflammatory Role of Cilostazol in Vascular Smooth Muscle Cells In vitro and In vivo 2010 ·Journal of Atherosclerosis and Thrombosis ·Chie Aoki, Yoshiyuki Hattori, Atsuko Tomizawa, Teruo Jojima, Kikuo Kasai	48
19	Telmisartan inhibits cytokine-induced nuclear factor-κB activation independently of the peroxisome proliferator-activated receptor-γ 2009 ·Hypertension Research ·(unknown), Yoshiyuki Hattori, Chie Aoki, Teruo Jojima, Kikuo Kasai	36
20	Aldosterone Impairs Vascular Endothelial Cell Function 2006 ·Journal of Cardiovascular Pharmacology ·(unknown), Kunihiro Suzuki, Teruo Jojima, Kohsuke Uchida, Yoshiyuki Hattori	74

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact